Barbara is passionate about science, so after completing a degree in natural sciences from Cambridge University and a PhD in molecular biology from Warwick University, she entered the IP profession and qualified as a European and Chartered Patent Attorney.
Type of clients and client work
Barbara’s clients know that they can rely on her to provide clear, commercially-focused advice to help them develop an IP strategy, secure robust protection for their innovation and navigate third party patents and related contentious issues. She enjoys building close relationships with her divergent client base, which includes start-ups, university spin-outs, well-established SMEs and multinational corporations, both from the UK and overseas, such as Scandinavia.
She has extensive experience in drafting, filing and prosecuting patent applications in the major global jurisdictions in Europe and beyond, including the US, Japan, China and Korea. Her expertise also includes the preparation of patentability opinions, freedom to operate analyses and advice regarding patent filing and licensing strategies. She also regularly handles opposition and appeal proceedings before the European Patent Office. Barbara particularly enjoys filing and advising on Supplementary Protection Certificates (SPCs).
Her specialism is in the life sciences and the portfolios that she handles span a wide variety of subject-matter including nucleic acid, polypeptide or small molecule based therapeutics and vaccines, stem cells, antibodies, diagnostic assays, and transgenic microorganisms. She also frequently deals with technologies where the biotechnology field intersects with other fields.
Qualifications and Memberships
- UK Chartered Patent Attorney, 2008
- European Patent Attorney, 2006
- Certificate in IP Law (with distinction), University of London, 2004
- Fellow of the Chartered Institute of Patent Attorneys (CIPA)
- Member of the European Patent Institute (EPI)
- Basic Litigation Skills Course, 2017
PhD, University of Warwick, “Physiology, biochemistry and genetics of microbial metabolism of linear alkanesulfanates”, 2003
MA (Hons), Natural Sciences, University of Cambridge, 1998
In May 2018, Barbara co-hosted a webinar regarding the seminal decision of the UK Supreme Court in Actavis v Eli Lilly (2017).
Having grown up in Belgium, Barbara is fluent in German and conversant in French.
She frequently provide updates and commentary on the IP industry and the Life Sciences sector; Please click here to review Barbara’s articles.